Therapeutic Effect of Bromocriptine as a Dopamine Agonist on Endometrioma Size: A Double-Blind Randomized Controlled Trial

Tahereh Poordast, M. Kandi, Elnaz Hosseini Najarkolaei, Elham Askari, Azizeh Farshbaf Khalili
In: International Journal of Women's Health and Reproduction Sciences · 2022 · vol. 13(1) , pp. 25–29 · doi:10.15296/ijwhr.2023.27 · W4414822668
RCT OA: diamond CC0
🔓 Open OA copy Full text JSON View on OpenAlex View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-06 ⓘ

This study found that combining bromocriptine with medroxyprogesterone significantly reduced ovarian endometrioma size and improved endometriosis symptoms more than medroxyprogesterone alone.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-06 · read from full text ⓘ

This double-blind randomized controlled trial studied 60 women with clinically or ultrasonographically confirmed residual ovarian endometriomas, comparing medroxyprogesterone plus bromocriptine versus medroxyprogesterone plus placebo over three months. Outcomes included changes in endometrioma size and endometriosis-related symptoms (pelvic pain, dysmenorrhea, and dyspareunia) assessed pre- and post-treatment, along with demographic characteristics. Both groups showed significant reductions in mean endometrioma size from baseline, but the Bromo group had significantly greater improvements in dysmenorrhea, dyspareunia, and pelvic pain than placebo (P < 0.01), with the combination producing a stronger overall effect than medroxyprogesterone alone. The paper’s conclusions are based on short-term (3-month) treatment and report efficacy differences without detailing longer-term follow-up limitations. This paper is centrally about endometriosis — specifically treatment effects of bromocriptine plus medroxyprogesterone on ovarian endometrioma size and endometriosis symptoms.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Objectives:This study aimed to assess the therapeutic effect of a dopamine agonist (bromocriptine) together with medroxyprogesterone for three months on ovarian endometrioma size. Materials and Methods: In this double-blind randomized clinical trial, 60 women with clinical or ultrasonographic evidence of residual ovarian endometriomas were randomly assigned into two groups (n=30/each): the Bromo group received medroxyprogesterone (20 mg) and bromocriptine (1.25 mg) twice a day orally for three months and the placebo group received medroxyprogesterone (20 mg) and placebo twice a day orally for three months. Demographic characteristics, pre- and posttreatment endometrioma size, pelvic pain, dysmenorrhea, and dyspareunia were compared in both groups. Results: Mean endometrioma size was significantly different in both groups compared with the pre-treatment stage (P<0.0001). Endometriosis symptoms of dysmenorrhea, dyspareunia, and pelvic pain improved after the treatment in Bromo group compared with placebo group (P<0.01). Conclusions: We found that medroxyprogesterone with placebo is effective in reducing the ovarian endometrioma size and also improves dysmenorrhea, dyspareunia, and pelvic pain, but the combination of medroxyprogesterone and bromocriptine has a stronger effect than using medroxyprogesterone alone.
Full text 3,217 characters · extracted from oa-doi-fallback · click to expand
Jan 2025, Vol 13, Issue 1 Advanced Search For Author's & Reviewer's Poll How do you find the scientific quality of the published articles on our web site? | Original Article | | | Therapeutic Effect of Bromocriptine as a Dopamine Agonist on Endometrioma Size: A Double-Blind Randomized Controlled Trial | | | Tahere Poordast1, Marziyeh Parizad Nasir Kandi2, Elnaz Hosseini Najarkolaei2, Elham Askari1, Azizeh Farshbaf Khalili3 | | | 1Infertility Research Center, Shiraz University of Medical Sciences, Shiraz, Iran 2Laparoscopy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran 3Physical Medicine and Rehabilitation Research Center, Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran | | | IJWHR 2025; 13: 025-029 DOI: 10.15296/ijwhr.2023.27 Viewed : 5024 times Downloaded : 4637 times. Keywords : Ovarian endometrioma, Dysmenorrhea, Dyspareunia, Pelvic pain, Bromocriptine | | | Full Text(PDF) | Related Articles | | | Abstract | | Objectives: This study aimed to assess the therapeutic effect of a dopamine agonist (bromocriptine) together with medroxyprogesterone for three months on ovarian endometrioma size. Materials and Methods: In this double-blind randomized clinical trial, 60 women with clinical or ultrasonographic evidence of residual ovarian endometriomas were randomly assigned into two groups (n=30/each): the Bromo group received medroxyprogesterone (20 mg) and bromocriptine (1.25 mg) twice a day orally for three months and the placebo group received medroxyprogesterone (20 mg) and placebo twice a day orally for three months. Demographic characteristics, pre- and post-treatment endometrioma size, pelvic pain, dysmenorrhea, and dyspareunia were compared in both groups. Results: Mean endometrioma size was significantly different in both groups compared with the pre-treatment stage (P < 0.0001). Endometriosis symptoms of dysmenorrhea, dyspareunia, and pelvic pain improved after the treatment in Bromo group compared with placebo group (P < 0.01). Conclusions: We found that medroxyprogesterone with placebo is effective in reducing the ovarian endometrioma size and also improves dysmenorrhea, dyspareunia, and pelvic pain, but the combination of medroxyprogesterone and bromocriptine has a stronger effect than using medroxyprogesterone alone. | Cite By, Google Scholar Articles by Poordast T Articles by Nasir Parizad Kandi M Articles by Hosseini Najarkolaei E Articles by Askari E Articles by Farshbaf Khalili A Articles by Tahere Poordast Articles by Marziyeh Parizad Nasir Kandi Articles by Elnaz Hosseini Najarkolaei Articles by Elham Askari Articles by Azizeh Farshbaf Khalili Submit Paper Online Submission System IJWHR ENDNOTE ® Style Tutorials Publication Charge Women's Reproductive Health Research Center About Journal Online Submission System IJWHR ENDNOTE ® Style Tutorials Publication Charge Women's Reproductive Health Research Center About Journal Publication Information Publisher Aras Part Medical International Press Editor-in-Chief Arash Khaki Mertihan Kurdoglu Deputy Editor Zafer Akan Aras Part Medical International Press Editor-in-Chief Arash Khaki Mertihan Kurdoglu Deputy Editor Zafer Akan Published Article Statistics

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosisendometriomadysmenorrheadyspareunia

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (23)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK